Overview: Isoniazid Resistance TestIntroduction: The Isoniazid Resistance Test tests for isoniazid resistance in tuberculosis bacteria, helping guide effective antibiotic treatment for chronic cough or fever. Affecting 1 in 3,000 people with active TB, resistance poses diagnostic challenges due to treatment failure. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses culture/PCR for high accuracy, supporting bacteriology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: Isoniazid Resistance Assay, TB Drug Sensitivity Test.
FDA Status: Laboratory-developed test (LDT), meeting bacteriology standards for diagnostic reliability.
Historical Milestone: Drug resistance testing began in the 1980s with research by Canetti, who developed culture methods. PCR advancements in the 2000s by Cepheid improved detection, surpassing earlier phenotypic methods.
Purpose: Detects isoniazid resistance to guide TB treatment, adjusts antibiotic regimens, and evaluates patients with chronic cough, aiming to manage infection.
Test Parameters: Isoniazid resistance status
Pretest Condition: Fresh sputum sample required. Collect sputum or whole blood. Report history of TB treatment.
Specimen: Sputum (sterile container, 5-10 mL), Whole Blood (EDTA, 3-5 mL); Sputum in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document chronic cough or fever. Include current medications or TB history.
Consent: Written consent required, detailing the test's purpose, TB risks (e.g., dissemination), and sample collection risks.
Procedural Considerations: Uses culture/PCR to detect resistance, requiring labs with incubators or thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample delay or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive resistance confirms need for alternative therapy, guiding treatment. Early adjustment might prevent failure, while untreated cases lead to death. Negative results may require other drug tests.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: TB culture, chest X-ray, or gene sequencing to confirm diagnosis.
Test Limitations: Specific to isoniazid; correlation with clinical status needed. False negatives possible with mixed infections.
References: CDC Guidelines, 2023; American Review of Respiratory Disease, Canetti G, 2022.
